Physician profile
Aiman Smer
NPI 1073825782
$1,326.93
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $167 · 2021: $556 · 2022: $29.40 · 2023: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $201.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $381.63 | 2021-2023 | Amplatzer Amulet |
| Boston Scientific Corporation | $311.68 | 2019-2021 | |
| Chiesi USA, INC. | $156.85 | 2019-2020 | |
| Amgen INC. | $80.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $72.94 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.78 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $54.52 | 2019-2023 | Xarelto |
| Pfizer INC. | $41.57 | 2019-2022 | |
| Lantheus Medical Imaging, INC. | $35.78 | 2023 | Definity |
| Actelion Pharmaceuticals US, INC. | $27.78 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.39 | 2019 | |
| Amarin Pharma, INC. | $23.91 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $16.53 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.91 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aiman Smer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.